Results 251 to 260 of about 15,304,481 (401)

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

open access: yesFEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee   +3 more
wiley   +1 more source

Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer. [PDF]

open access: yesBMC Cancer
Wang A   +13 more
europepmc   +1 more source

Overexpression of CDT1 inhibits cell cycle progression at S phase by interacting with the mini‐chromosome maintenance complex and causes DNA damage

open access: yesFEBS Open Bio, EarlyView.
CDT1 is an essential protein for DNA replication licensing that loads the MCM complex, the eukaryotic replicative DNA helicase, onto replication origins. Overexpression of CDT1 induces cell cycle arrest at the S phase. Here we showed CDT1 inhibits the progression of replication forks by interacting with the MCM complex, leading to the stalling and ...
Takashi Tsuyama   +7 more
wiley   +1 more source

Arginine dependence of tumor cells: targeting a chink in cancer’s armor

open access: yesOncogene, 2016
M. Patil   +4 more
semanticscholar   +1 more source

HSP70 governs permeability and mechanotransduction in primary human endothelial cells

open access: yesFEBS Open Bio, EarlyView.
HSP70 chemical inhibition reduces endothelial cell proliferation and increases permeability, the latter supported by normal interendothelial junctional protein distribution. HSP70 also plays a role in shear stress response, a hemodynamic force naturally present in blood vessels and correlated with vessel protection.
Andrea Pinto‐Martinez   +5 more
wiley   +1 more source

Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells. [PDF]

open access: yesFront Immunol
Liu X   +9 more
europepmc   +1 more source

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer

open access: diamond, 2015
Hisao Imai   +14 more
openalex   +1 more source

Homologous expression and purification of human HAX‐1 for structural studies

open access: yesFEBS Open Bio, EarlyView.
This research protocol provides detailed instructions for cloning, expressing, and purifying large quantities of the intrinsically disordered human HAX‐1 protein, N‐terminally fused to a cleavable superfolder GFP, from mammalian cells. HAX‐1 is predicted to undergo posttranslational modifications and to interact with membranes, various cellular ...
Mariana Grieben
wiley   +1 more source

Home - About - Disclaimer - Privacy